On May 18, 2021 Light Chain Bioscience | Novimmune SA reported that under its global collaboration agreement with TG Therapeutics (NSDAQ: TGTX) a predefined milestone was reached in the clinical development of TG-1801 (NI-1701), a bispecific antibody targeting CD19 and CD47 (Press release, Light Chain Bioscience, MAY 18, 2021, View Source [SID1234580208]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited with the progress of TG-1801 in the current Phase I clinical trial in Australia by our partner TG Therapeutics, as well as the recent approval of an IND and start of Phase I in the US. TG-1801 is the first bispecific antibody allowing for selective CD47 targeting on tumor cells, a unique mechanism of action that we are deploying in other internal and partnered bispecific programs for the treatment of cancer" said Nicolas Fischer CEO of Light Chain Bioscience. "The clinical progress of TG-1801 brings further validation to our bispecific kappa-lambda body format that maintains the native structure of a human IgG."